• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
NTI

NEUROTECH INTERNATIONAL LIMITED - News & Media

7.69% ! 1.4¢
Market Cap $14.69M  !
Healthcare Biotechnology
Add to My Watchlist

Neurotech International Limited is an Australia-based clinical-stage biopharmaceutical... Neurotech International Limited is an Australia-based clinical-stage biopharmaceutical development company. The Company is focused predominately on pediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. It has completed a Phase II/III randomized, double-blind, placebo-controlled clinical trial in autism spectrum disorder (ASD) with clinically significant benefits reported across a number of clinically validated measures and safety. In addition, it has completed and reported significant and clinically meaningful Phase I/II trials in ASD and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. NTI164 is being developed as a therapeutic drug product for a range of neurological disorders in children where neuroinflammation is involved.More

Articles & Videos

Neurotech bounces back from FDA rejection with new NTI164 baseline study

Neurotech (ASX:NTI) has bounced back from a recent fast-track status rejection from the FDA, now launching a NTI164 baseline data study.

25 Nov 2024 10:37 (AEDT)

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Neurotech International (NTI) has flagged to its shareholders that the FDA hasn't granted its product NTI164 orphan drug status.

04 Oct 2024 09:57 (AEST)

Neurotech International (ASX:NTI) treats first patient in paediatric clinical trial

Neurotech International (ASX:NTI) has treated its first patient in its phase one and two paediatric clinical trials.

16 Feb 2023 15:09 (AEDT)

Neurotech International (ASX:NTI) gains green light to begin paediatric clinical trials

Neurotech International (NTI) has been given the green light to begin its phase one and two paediatric clinical trials in Australia.

27 Jan 2023 14:11 (AEDT)



Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
1.4¢ 		Change
0.001(7.69%) 		Mkt cap ! $14.69M
Open High Low Value Volume
1.3¢ 1.4¢ 1.3¢ $4.026K 307.2K

Buyers (Bids)

No. Vol. Price($)
1 1917576 1.3¢
 

Sellers (Offers)

Price($) Vol. No.
1.4¢ 505017 5
View Market Depth
Last trade - 16.10pm 29/08/2025 (20 minute delay) ?
NTI (ASX) Chart

Top Stories

'These things happen': Lakes Blue not worried by mud motor issue at Wombat-5 Well

Lakes Blue Energy has dropped the latest on its Wombat-5 Well, and while it's been a bit of a slow burn, things are now back on track.
Flat revenue YoY saves day for Cettire; shares up above 30c on FY25 results Embattled online luxury retailer Cettire has clocked a rare green day Friday – or what feels like one – on the back of its FY25 results.
Stellar Harvey Norman results 'a testament to strength of our diversified model' Harvey Norman rocketed +10% after unveiling a bumper set of numbers for FY25, showing the behemoth retail giant is firing on all cylinders.
Week 35 Wrap: If Invictus is above 15c again, the ASX is back baby. Even under 9,000pts By and large, the big story this week that captured HotCopper users’ attention, and that of local market punters everywhere, was the astonishing comeback of Invictus Energy. Invictus has spent years in the doldrums, driven largely by shareholder impatience in the stock, which it f...
The 5% deposit scheme: A golden ticket or ticking time bomb? The government has just handed first home buyers what looks like a golden ticket, but it could be the fuse for a ticking time bomb.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.From October,...
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.